Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?

Degrassat-Théas A, Paubel P, Parent de Curzon O, Le Pen C, Sinègre M

DOI: 10.1007/s40273-013-0039-4
Published: 2013 Apr
Container: PharmacoEconomics
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40273-013-0039-4,
  title = {Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?},
  author = {Degrassat-Théas A and Paubel P and Parent de Curzon O and Le Pen C and Sinègre M},
  year = {2013},
  journal = {PharmacoEconomics},
  doi = {10.1007/s40273-013-0039-4},
  url = {https://doi.org/10.1007/s40273-013-0039-4}
}

RIS

TY  - JOUR
TI  - Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
AU  - Degrassat-Théas A
AU  - Paubel P
AU  - Parent de Curzon O
AU  - Le Pen C
AU  - Sinègre M
PY  - 2013
JO  - PharmacoEconomics
DO  - 10.1007/s40273-013-0039-4
UR  - https://doi.org/10.1007/s40273-013-0039-4
ER  -

APA

A, D., P, P., O, P. D. C., C, L. P., & M, S. (2013). Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?. PharmacoEconomics. https://doi.org/10.1007/s40273-013-0039-4

Source records

pubmed · retrieved 2026-09-26T17:56:21.304Z